Top blocks from Dallas Mavericks vs. New York Knicks, 04/16/2021
Top blocks from Dallas Mavericks vs. New York Knicks, 04/16/2021
Thiruvananthapuram (Kerala) [India], May 6 (ANI): Kerala Chief Minister Pinarayi Vijayan on Thursday announced a state-wide lockdown starting Saturday till May 16 to tackle the second wave of COVID-19 situation in the state.
The GAVI vaccine alliance on Thursday welcomed U.S. President Joe Biden's support for waiving intellectual property rights for COVID-19 vaccines and also urged Washington to help manufacturers transfer know-how to boost global production. The Geneva-based group, which co-leads the COVAX dose-sharing programme with the World Health Organization (WHO), faces major supply constraints after India suspended vaccine exports due to its major COVID-19 epidemic. "We recognise also the significance of the (Biden) administration’s commitment to work towards increasing raw material production, which will have an immediate impact on alleviating current global supply constraints," it told Reuters in a statement.
Colorado Avalanche (34-13-4, second in the West Division) vs. Los Angeles Kings (21-24-6, sixth in the West Division) Los Angeles; Friday, 10 p.m. EDT FANDUEL SPORTSBOOK LINE: Kings +227, Avalanche -286 BOTTOM LINE: Nathan MacKinnon and Colorado square off against Los Angeles. He ranks third in the in the NHL with 65 points, scoring 20 goals and totalling 45 assists. The Kings are 21-24-6 against opponents from the West Division. Los Angeles has given up 23 power-play goals, killing 84% of opponent chances. The Avalanche are 34-13-4 against West Division teams. Colorado ranks 10th in the NHL with 34.7 shots per game and is averaging 3.5 goals. In their last meeting on March 14, Colorado won 4-1. TOP PERFORMERS: Dustin Brown leads the Kings with 17 goals and has 31 points. Trevor Moore has five goals and two assists over the last 10 games for Los Angeles. Mikko Rantanen leads the Avalanche with 29 goals and has 59 points. Andre Burakovsky has five goals and four assists over the last 10 games for Colorado. LAST 10 GAMES: Kings: 5-5-0, averaging 2.5 goals, 4.1 assists, 2.8 penalties and 5.9 penalty minutes while giving up 2.9 goals per game with a .902 save percentage. Avalanche: 6-4-0, averaging 3.2 goals, 5.6 assists, 3.9 penalties and 8.1 penalty minutes while giving up 2.9 goals per game with an .896 save percentage. INJURIES: Kings: None listed. Avalanche: Jacob MacDonald: out (lower body), Bowen Byram: out (upper body), Brandon Saad: out (lower-body), Matt Calvert: out (undisclosed), Dennis Gilbert: out (face). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Philadelphia Flyers (23-23-7, sixth in the East Division) vs. Washington Capitals (34-14-5, first in the East Division) Washington; Friday, 7 p.m. EDT FANDUEL SPORTSBOOK LINE: Capitals -200, Flyers +165 BOTTOM LINE: Washington hosts the Philadelphia Flyers after T.J. Oshie scored three goals in the Capitals' 4-2 victory over the Rangers. The Capitals are 34-14-5 in division play. Washington averages 9.4 penalty minutes per game, the fourth-most in the NHL. Tom Wilson leads the team serving 84 total minutes. The Flyers are 23-23-7 against the rest of their division. Philadelphia has scored 31 power-play goals, converting on 19.5% of chances. In their last meeting on April 17, Washington won 6-3. Alex Ovechkin scored two goals for the Capitals. TOP PERFORMERS: Nicklas Backstrom leads the Capitals with 38 assists and has 53 points this season. John Carlson has seven assists over the last 10 games for Washington. Scott Laughton leads the Flyers with a plus-11 in 50 games this season. Claude Giroux has five goals and five assists over the last 10 games for Philadelphia. LAST 10 GAMES: Capitals: 6-3-1, averaging 3.2 goals, 5.2 assists, 4.5 penalties and 14.9 penalty minutes while giving up 2.8 goals per game with an .891 save percentage. Flyers: 3-6-1, averaging 2.8 goals, 4.7 assists, 3.6 penalties and 8.4 penalty minutes while giving up 3.6 goals per game with an .876 save percentage. INJURIES: Capitals: Tom Wilson: day to day (upper body), Evgeny Kuznetsov: day to day (covid-19), Alex Ovechkin: day to day (lower body), Michal Kempny: out (lower body), Daniel Sprong: day to day (illness), Justin Schultz: day to day (lower body). Flyers: Tanner Laczynski: out for season (hip), Carter Hart: out for season (left knee). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Anaheim Ducks (17-30-7, eighth in the West Division) vs. Minnesota Wild (33-14-5, third in the West Division) St. Paul, Minnesota; Friday, 8 p.m. EDT FANDUEL SPORTSBOOK LINE: Wild -280, Ducks +222 BOTTOM LINE: Minnesota hosts the Anaheim Ducks after Kirill Kaprizov scored two goals in the Wild's 3-2 overtime loss to the Golden Knights. The Wild are 33-14-5 against opponents in the West Division. Minnesota has scored 169 goals and is 10th in the NHL averaging 3.2 per game. Kaprizov leads the team with 26. The Ducks are 17-30-7 in division matchups. Anaheim has surrendered 32 power-play goals, killing 79.6% of opponent opportunities. In their last meeting on March 24, Minnesota won 3-2. Jared Spurgeon scored a team-high two goals for the Wild in the victory. TOP PERFORMERS: Jordan Greenway leads the Wild with 25 assists and has 31 points this season. Kevin Fiala has six goals and seven assists over the last 10 games for Minnesota. Maxime Comtois leads the Ducks with 14 goals and has 30 points. Cam Fowler has two goals and four assists over the last 10 games for Anaheim. LAST 10 GAMES: Wild: 7-1-2, averaging 4.3 goals, 6.7 assists, 2.7 penalties and 6.3 penalty minutes while giving up three goals per game with a .904 save percentage. Ducks: 3-7-0, averaging 1.8 goals, 2.9 assists, 3.1 penalties and 6.8 penalty minutes while giving up 2.9 goals per game with a .901 save percentage. INJURIES: Wild: Kevin Fiala: day to day (lower body). Ducks: Jakob Silfverberg: out (lower body). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Dallas Stars (21-18-14, fifth in the Central Division) vs. Tampa Bay Lightning (36-14-3, second in the Central Division) Tampa, Florida; Friday, 7 p.m. EDT FANDUEL SPORTSBOOK LINE: Lightning -162, Stars +132 BOTTOM LINE: Tampa Bay hosts Dallas trying to extend its four-game home winning streak. The Lightning are 36-14-3 against the rest of their division. Tampa Bay ranks seventh in the league recording 8.9 points per game, averaging 3.3 goals and 5.5 assists. The Stars are 21-18-14 against the rest of their division. Dallas has given up 30 power-play goals, killing 79% of opponent chances. The teams square off for the second straight game. TOP PERFORMERS: Brayden Point leads the Lightning with 23 goals, adding 25 assists and collecting 48 points. Blake Coleman has five goals over the last 10 games for Tampa Bay. Joe Pavelski leads the Stars with 22 goals and has 46 points. Jason Robertson has four goals and seven assists over the last 10 games for Dallas. LAST 10 GAMES: Lightning: 7-2-1, averaging 3.2 goals, 4.4 assists, 3.4 penalties and 8.2 penalty minutes while giving up two goals per game with a .923 save percentage. Stars: 4-4-2, averaging 2.3 goals, 3.5 assists, 2.8 penalties and seven penalty minutes while allowing 3.1 goals per game with an .886 save percentage. INJURIES: Lightning: None listed. Stars: None listed. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Detroit Red Wings (18-27-9, eighth in the Central Division) vs. Columbus Blue Jackets (17-25-12, seventh in the Central Division) Columbus, Ohio; Friday, 7 p.m. EDT FANDUEL SPORTSBOOK LINE: Blue Jackets -134, Red Wings +110 BOTTOM LINE: The Detroit Red Wings visit Columbus after Oliver Bjorkstrand scored two goals in the Blue Jackets' 4-2 victory against the Predators. The Blue Jackets have gone 17-25-12 against division opponents. Columbus has given up 26 power-play goals, killing 80% of opponent chances. The Red Wings are 18-27-9 against Central Division opponents. Detroit is the last-ranked team in the league averaging just 5.7 points per game. Jakub Vrana leads the team with 7 total points. In their last meeting on April 27, Columbus won 1-0. TOP PERFORMERS: Bjorkstrand leads the Blue Jackets with 17 goals and has 42 points. Emil Bemstrom has three goals over the last 10 games for Columbus. Dylan Larkin leads the Red Wings with 23 points, scoring nine goals and collecting 14 assists. Vrana has six goals and one assist over the last 10 games for Detroit. LAST 10 GAMES: Blue Jackets: 2-5-3, averaging 1.7 goals, 3.4 assists, 2.9 penalties and eight penalty minutes while giving up 3.1 goals per game with a .909 save percentage. Red Wings: 3-4-3, averaging 1.8 goals, 2.7 assists, 3.2 penalties and 6.7 penalty minutes while allowing two goals per game with a .943 save percentage. INJURIES: Blue Jackets: Joonas Korpisalo: out for season (lower body). Red Wings: Robby Fabbri: out (upper body), Frans Nielsen: out for season (lower body), Dylan Larkin: out (upper body). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Arizona Coyotes (22-26-6, fifth in the West Division) vs. San Jose Sharks (21-26-6, seventh in the West Division) San Jose, California; Friday, 10:30 p.m. EDT FANDUEL SPORTSBOOK LINE: Sharks -104, Coyotes -117 BOTTOM LINE: Arizona comes into the matchup with San Jose as losers of three in a row. The Sharks are 21-26-6 against the rest of their division. San Jose averages 9.4 penalty minutes per game, the sixth-most in the NHL. Kurtis Gabriel leads the team serving 55 total minutes. The Coyotes are 22-26-6 against opponents in the West Division. Arizona has given up 32 power-play goals, killing 80.2% of opponent chances. In their last meeting on April 28, San Jose won 4-2. TOP PERFORMERS: Evander Kane has 48 total points for the Sharks, 22 goals and 26 assists. Tomas Hertl has six goals over the last 10 games for San Jose. Phil Kessel leads the Coyotes with 18 goals and has 38 points. Jakob Chychrun has five goals and four assists over the last 10 games for Arizona. LAST 10 GAMES: Sharks: 3-5-2, averaging 2.9 goals, 4.2 assists, 3.8 penalties and 7.9 penalty minutes while giving up 3.5 goals per game with an .894 save percentage. Coyotes: 3-6-1, averaging 2.5 goals, 4.4 assists, 2.9 penalties and 5.8 penalty minutes while allowing 2.6 goals per game with a .901 save percentage. INJURIES: Sharks: Radim Simek: day to day (upper body), Matt Nieto: out (lower body). Coyotes: Nick Schmaltz: day to day (upper body). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
St. Louis Blues (24-19-8, fourth in the West Division) vs. Vegas Golden Knights (37-13-2, first in the West Division) Paradise, Nevada; Friday, 10 p.m. EDT FANDUEL SPORTSBOOK LINE: Golden Knights -148, Blues +120 BOTTOM LINE: Vegas hosts St. Louis looking to prolong its five-game home winning streak. The Golden Knights are 37-13-2 against the rest of their division. Vegas is fifth in the league recording 9.1 points per game, averaging 3.4 goals and 5.8 assists. The Blues are 24-19-8 against the rest of their division. St. Louis has given up 37 power-play goals, killing 76.4% of opponent opportunities. In their last meeting on April 7, St. Louis won 3-1. TOP PERFORMERS: Max Pacioretty leads the Golden Knights with 24 goals and has 51 points. Mark Stone has seven goals and six assists over the last 10 games for Vegas. Ryan O'Reilly leads the Blues with a plus-21 in 51 games this season. David Perron has eight assists over the last 10 games for St. Louis. LAST 10 GAMES: Golden Knights: 8-2-0, averaging 3.7 goals, 6.1 assists, 3.6 penalties and 7.5 penalty minutes while giving up 2.1 goals per game with a .927 save percentage. Blues: 5-3-2, averaging 3.3 goals, 5.6 assists, 3.1 penalties and 7.9 penalty minutes while allowing 2.8 goals per game with a .907 save percentage. INJURIES: Golden Knights: Tomas Nosek: out (undisclosed), Max Pacioretty: day to day (undisclosed). Blues: Mackenzie MacEachern: out (upper body), Vladimir Tarasenko: day to day (lower-body), Torey Krug: day to day (upper body), Vince Dunn: day to day (upper body), Carl Gunnarsson: out for season (lower body), Oskar Sundqvist: out for season (knee). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
New York Rangers (26-22-6, fifth in the East Division) vs. Boston Bruins (31-14-7, third in the East Division) Boston; Thursday, 7 p.m. EDT FANDUEL SPORTSBOOK LINE: Bruins -207, Rangers +172; over/under is 5.5 BOTTOM LINE: New York enters the matchup with Boston as losers of four games in a row. The Bruins are 31-14-7 against the rest of their division. Boston leads the NHL with nine shorthanded goals, led by Brad Marchand with four. The Rangers are 26-22-6 against the rest of their division. New York is 10th in the league averaging 5.5 assists per game, led by Artemi Panarin with 1.0. In their last meeting on March 13, New York won 4-0. TOP PERFORMERS: Marchand leads the Bruins with 63 points, scoring 27 goals and adding 36 assists. David Krejci has five goals over the last 10 games for Boston. Mika Zibanejad leads the Rangers with 22 goals and has 48 points. Panarin has one goal and seven assists over the last 10 games for New York. LAST 10 GAMES: Bruins: 7-2-1, averaging 3.7 goals, 6.6 assists, 3.8 penalties and 8.6 penalty minutes while giving up 1.9 goals per game with a .931 save percentage. Rangers: 4-6-0, averaging 2.6 goals, 4.8 assists, 4.4 penalties and 14.9 penalty minutes while allowing 3.1 goals per game with a .902 save percentage. INJURIES: Bruins: None listed. Rangers: Ryan Lindgren: day to day (upper body), Jack Johnson: out (sports hernia), Artemi Panarin: out (lower body), Chris Kreider: day to day (lower body), Brett Howden: out (foot), Julien Gauthier: day to day (lower body), Jacob Trouba: day to day (upper body). ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Spain is moving aggressively to land new battery and electric vehicle plants, using billions of European Union pandemic relief funds to avoid being left behind as the global auto sector undertakes the biggest technology transformation in a century. As Europe's second largest car-producing nation behind Germany, and with the automotive sector accounting for 10% of its economy, Spain has a lot to lose as automakers overhaul supply chains and manufacturing for electric vehicles. Germany and number three European producer France are already pouring funds into battery plants, supporting their respective national champion automakers, and both Volkswagen and Renault are investing heavily in EVs on their home turf.
Volkswagen Group's after-tax profit rebounded strongly to 3.4 billion euros ($4.1 billion) in the first three months of the year as sales rebounded in China, the company's largest single market, and as customers went for the more profitable models in the company's lineup. Sales revenues in the first quarter of 2021 rose by 13% to 62.3 billion euros, boosted by a strong rebound of 61.4 percent in unit sales as China reopened after being hard-hit by the pandemic in the first quarter of 2020. The company said it expected sales to customers would be “significantly up” from the previous year, assuming successful containment of the COVID-19 pandemic.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease (“Alzheimer’s”). Akome’s ‘next-generation’ psychedelic drug formulation, also known as AKO002, is comprised of the psychedelic compound psilocybin and a plant bioactive which, when combined together, are believed to be complementary and/or synergistic in the treatment of Alzheimer’s. A provisional matter of composition patent application for AKO002 has been filed with the United States Patent and Trademark Office (USPTO) under application number 63123838. Alzheimer’s is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. It is a progressive neurological disorder characterized by extracellular amyloid protein deposition and intracellular tau protein aggregates that, in accumulation, are associated with a variety of pathological processes including microtubular damage, axonal transport disruption and, ultimately, cell death. The hippocampus, a key structure in the ability to learn and retain information and a site for neurogenesis, is particularly vulnerable to Alzheimer’s pathology, including increased inflammation, and one of the earliest parts of the brain to be affected by the disease. Current approaches of treating Alzheimer’s focus mainly on treating symptoms of the disease, however available drugs do not change the underlying disease process. Currently there are no disease-modifying treatments for Alzheimer’s. Akome’s data analysis and mapping reveals anecdotal evidence that psychedelics have positive effects in the promotion of neuroplasticity and neurogenesis and act as agonists at serotonin receptors, including the 5HT2A receptors (5HT2A-R), that appear in high concentrations, in regions of the brain that are vulnerable to Alzheimer’s, such as the hippocampus. Additionally, psychedelics have been shown to have potent anti-inflammatory properties, and given their affinity for the 5HT2A-R, may represent a unique anti-inflammatory overwhelmingly targeted to brain tissue. Akome’s plant bioactive seems to work in a complementary way with the psilocybin compound, as it has several mechanisms of action including β-amyloid reduction and increased cerebral blood flow. Akome will continue to develop on its initial data mapping, and analysis of its bioactive-psilocybin, as it sets the process for stage two of its novel AKO002 psychedelic drug formulation and its advancement for the treatment of Alzheimer’s Disease. “Akome’s novel drug formulation for the treatment of Alzheimer’s could be a revolutionary development for the world of neurological science, and a life changer for the millions of people who are suffering from this devastating disease. We are very excited at the prospect of this drug formulation, as it reaches a relatively untapped patient base for psychedelic treatment.” stated Joel Shacker CEO of the Company. About Core One Labs Inc. Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders. Core One Labs Inc. Joel ShackerChief Executive Officer FOR MORE INFORMATION, PLEASE CONTACT: email@example.com 1-866-347-5058 Cautionary Disclaimer Statement: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
Japan's Nintendo Co Ltd on Thursday forecast Switch console sales to reach 25.5 million units in the financial year that started April 1, signalling expectations of the hit device peaking. Nintendo sold 28.8 million Switch consoles in the year ended March 31. With Nintendo a major beneficiary of the COVID-19 pandemic-induced gaming boom, market participants are now focused on whether the Switch can maintain momentum in its fifth year of life amid speculation over new games and a hardware refresh.
The role of the Sackler family and their company, Purdue Pharma, in developing the prescription painkiller OxyContin is familiar territory. Gibney’s film digs into the aftermath, including the push to get doctors to overprescribe the medication and the company’s use of former government regulators to cripple serious oversight.
New Delhi [India], May 6 (ANI): The COVID-19 vaccination drive, which began for people under the 18-44 age group is currently underway at 301 centres across the national capital.
Company Announcement Copenhagen, 6 May 2021 No. 15/2021 Acquisition of ISS A/S shares by Group CFO ISS A/S (ISS.CO, ISS DC, ISSDY), a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by persons discharging managerial responsibilities in ISS A/S and/or their closely associated persons. Group CFO Kasper Fangel has purchased 1,557 shares in ISS A/S (as described in attached notification) and now holds a total of 4,192 shares in the company. For investor enquiries Michael Bjergby, Head of Group Investor Relations, +45 31 37 41 71 Louisa Baruch Larsson, Senior Investor Relations Manager, +45 38 17 63 38 For media enquiries Kenni Leth, Head of Global PR & Media Relations, +45 51 71 43 68 About ISS ISS is a leading workplace experience and facility management company. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. In 2020, ISS Group’s global revenue amounted to DKK 70 billion. For more information on the ISS Group, visit www.issworld.com. ISS A/S, ISIN DK0060542181, ISIN US4651472056, ISS Global A/S, ISIN XS2013618421, ISIN XS1145526825, ISIN XS1673102734, ISS Finance B.V., ISIN XS2199343513 Attachments ISS Announcement 060521 - Kasper Fangel shares PDMR reporting - Kasper Fangel
COLUMBUS, Ohio — When the pandemic passed the one-year mark, Lisa Phillips wasn't exactly eager to walk down memory lane. She had developed symptoms and quarantined with a suspected case of COVID-19 last spring, lost her mother to the disease in July and been hospitalized in November from what she describes as a nervous breakdown fueled by grief and isolation. But Phillips also wasn’t ready to delete the apps that provide those reminders that showed her each day what she'd shared on social media just a year earlier. That pain, she says, shouldn't be forgotten. So she still wanted to save the memories — but for later. As we navigate these weeks that are unspooling a year after March, April and May 2020, memories from earlier in the COVID-19 crisis are popping up in people's social media feeds when throwbacks, reposts and commemorations crack open the digital time capsule of the pandemic before it's even over. Out spill the first reminders of a zillion virus-inflected anniversaries, ranging from the relatively trivial to the tragic: the empty toilet paper shelves, the new masks, the start of remote work or school, the gratitude to exhausted health care staff, the In Memoriams. For Phillips, 42, of Phoenix, the trauma still feels fresh. “If you’re not ready to relive the anniversary and beginning of this ongoing pandemic, you’re not alone,” she tweeted. Social media's insistence on serving our own experiences back up to us — even if desired — can complicate the coping. But experts say it also provides opportunities to realize connection — and to frame how we move forward. “In certain ways — not all ways — we have more in common with more people on the planet than we probably have in any other year,” says Jamil Zaki, a Stanford University psychologist who researches empathy. People's circumstances vary widely, and the pandemic has exposed lots of inequities, disproportionately impacting communities of colour. “But at some level," Zaki says, “many of us are dealing with a very similar type of anxiety, uncertainty, mourning and loss.” Zillah Wesley, an organizer with the anti-poverty Poor People’s Campaign in Washington, D.C., says she has known more than 40 people who have died during the pandemic, including several relatives and friends' relatives. Many of them died in the early months, she says, and nearly all of them were fellow members of the Black community. Now posts about them are showing up again on her smartphone, she says, bringing a sinking feeling of loss. “I sit with it and just let it flow through me so it won’t pop up in other ways," she says. “It’s like you can click off the thing and still go about your day, but the person is still gone.” The pandemic has been a collective trauma, and sharing personal emotional experience can help people feel supported and find meaning in that, says Sara Levens, a University of North Carolina at Charlotte psychology professor whose lab studies emotion. Some people may find it helpful to look back on their own or others’ experiences and reflect on what they’ve learned, what's been lost and gained, or where they’ve seen resilience or joy in the midst of greater hardship. To navigate that content in a healthy way, experts recommend that people pay attention to what kind of social media posts and stories they're viewing — how the content makes them feel and whether they're actually getting something useful from it. “Just like you would be mindful of doom-scrolling, I think we need to be mindful of pandemic-scrolling,” says Elana Newman, a University of Tulsa psychologist and trauma researcher. If the posts you're reading start to feel more overwhelming and less like you're plugging into shared experience, it's probably a good idea to disengage and distract yourself with an activity that helps replenish you, Levens says. Disabling social media notifications and muting or unfollowing accounts that negatively impact your mental health can help. Some users are even more proactive, intentionally limiting how they use digital tools that resurface their own memories. Brian Acunis, a soon-to-be graduate student who has lived part of the past year in New York, says he deleted the reminiscing app Timehop from his phone just a few months into the pandemic. He gave up a three-year streak with it because he didn’t want to keep seeing memories of all the activities and friends he was missing. “It just was too sad of a reminder,” says Acunis, 28. That tension isn't lost on the folks behind the app. In March, on the anniversary of the pandemic declaration, Timehop tweeted a reminder that users can hide unwanted memories, noting they sometimes “need to be put away.” There's no surge in use of that option so far. But if things change in the coming months, Timehop might consider altering how people hide memories or encouraging breaks if that would benefit users, CEO Matt Raoul says. “We try to balance that mantra of ‘we do not want to curate your memories and we want to show you everything’ with giving people the tools to control it in a way that’s best for them,” Raoul says. Phillips, a vice-president at a cloud computing services company, now skips Timehop and social media altogether on days when her grief feels especially sharp or she doesn't have mental or emotional space for what they might serve up. She says she also seeks help from others through professional care, therapy and talking with family and friends. She still considers it valuable to document moments and milestones on social media so she can look back at the difference over time. “There's a part of me,” she says, “that doesn't want to lose the sort of archival element.” Zaki, too, thinks the pandemic is worth remembering — not only because of what it caused, but because of what it revealed about the loneliness, depression and anxiety that people increasingly felt even before it descended. “I really hope we don’t forget this time and don’t just snap back into whatever normal was before, because normal before was not that normal. ... We were fracturing as a culture. Trust was diminishing," Zaki says. “And I think that in a lot of ways the pandemic, like other disasters, exposes some deep truths about who we are, what we need and who we can be." Kantele Franko, The Associated Press
(Bloomberg) -- Societe Generale SA turned in its best equities-trading performance since 2015, rebounding from a disastrous quarter a year earlier and providing relief to Chief Executive Officer Frederic Oudea as he prepares to unveil his new investment bank strategy.Revenue at the equities business -- hit last year by market volatility -- was the high point in a strong trading quarter for the French bank, soaring to 851 million euros ($1.02 billion) compared with analyst estimates of 573 million euros. Fixed income revenue and provisions were also better-than-expected.European and Wall Street banks reported their best equities revenue in years after booming stock markets and retail-investor volatility during the height of the pandemic continued into the new year. The rally is easing pressure on Oudea after the bank’s first annual loss in more than three decades last year, prompting him to reshuffle top management and pledge buybacks.“Market conditions were very positive in the beginning of the year, and there’s always a seasonality,” Oudea said in an interview with Bloomberg TV on Thursday. “But we are confident for the overall year.”SocGen rose as much as 4.5% in early Paris trading and gained 4.3% as of 9:05 a.m., taking this year’s increase to about 45%. Equities revenue was hammered in the first half of 2020 by losses on structured products hurt by companies canceling dividends, triggering a review and a 684 million-euro writedown at the unit. SocGen is cutting about 450 million euros of costs until 2023 at the business and has designed new products. Still, its equities performance since then has been uneven, with gains in the third quarter giving way to declines in the fourth.The first-quarter performance of the equities unit “shows that the franchise is really intact, and that we made the right decision to redesign the portfolio of structured products,” Oudea said.In a bid to boost profitability, he’s started cutting hundreds of jobs at the investment-banking unit and merged the domestic retail networks to reduce the number of branches. Last month, SocGen also agreed to sell its 170-billion euro asset management arm Lyxor to Amundi for 825 million euros. The deal accelerates the bank’s exit from asset management, even as the sector shows higher valuation multiples, making it a growth priority for some peers.French rival BNP Paribas -- which also saw equities income erased a year earlier -- posted its best quarter from that business since 2018, though couldn’t match SocGen’s performance in fixed income, where it missed estimates. On Friday, Barclays Plc’s equities unit reported a 65% year-on-year jump in equities revenue, making it its best quarter ever.Elsewhere, the implosion of Bill Hwang’s Archegos Capital Management spoiled what would otherwise have been strong trading performances by the Swiss banks. U.S. banks’ equity-underwriting fees were almost quadruple their first-quarter 2020 level in aggregate, according to Bloomberg Intelligence, marking the third quarter in a row of growth more than doubling.SocGen’s investment bank saw its revenue soar 54% to about 2.5 billion euros in the first three months topping analysts’ estimates. The division’s new head, Slawomir Krupa, will update strategy on Monday, just as the unit is dealing with a round of job cuts announced in November.During the first quarter, SocGen also joined other European lenders in posting lower provisions and set aside 276 million euros to cover potential bad loans, less than the the 715.8 million euros that analysts anticipated. The lender expects its cost of risk for the year at between 1.6 billion euros and 1.85 billion euros, or about half its 2020 level.Many big European lenders have bolstered profit by stashing less money for doubtful loans than last year or by freeing up reserves. Deutsche Bank AG, Banco Santander SA and Lloyds Banking Group Plc are among the firms to argue that rosier economic prospects justify such moves.SocGen’s CET1 ratio, a key measure of its capital strength, rose to 13.5%, above analysts estimates. The bank expects the Lyxor deal to have a positive impact of about 18 basis points on its core capital ratio, while share buybacks should have a negative impact of 13 basis points.Other highlights of SocGen’s earnings:Revenue EU6.24b vs EU5.89b est.Global Markets EU1.65b vs. EU1.31b est.Fixed Income & Currencies EU625m vs. EU569.7M est.Equities & Prime Services EU851m vs. EU572.7M est.CET1 Ratio 13.5% vs. 12.99% est.Net income EU814m vs. EU258.3M(Updates with shares in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
A third arrest has been made after a 21-year-old man was stabbed to death at a London shopping centre. Gedeon Ngwadema was attacked at Brent Cross mall at 6.45pm on Tuesday after reports that a fight broke out. On Wednesday, officers arrested a 20-year-old man on suspicion of murder at his home in Harrow, north west London.